Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkısh oncology group study.

Autor: Acar R; Department of Medical Oncology, Mersin City, Research and Training Hospital, University of Health Science, Mersin, Turkey., Paydaş S; Department of Medical Oncology, School of Medicine, University of Cukurova, Adana, Turkey., Yıldırım M; Department of Hematology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey., Kılıçarslan E; Department of Medical Hematology, Sultan Abdulhamid Han Research and Training Hospital, University of Health Science, Istanbul, Turkey., Sahın U; Department of Hematology, Medicana International Hospital, Ankara, Turkey., Dogan A; Department of Hematology, Van Yuzuncu Yil School of Medicine, University of Van Yuzuncu Yil, Van, Turkey., Guven DC; Department of Medical Oncology, Hacettepe School of Medicine, University of Hacettepe, Ankara, Turkey., Ekıncı O; Department of Hematology, Fırat School of Medicine, University of Fırat, Elazıg, Turkey., Tıglıoglu M; Department of Hematology, Dıskapı Research and Training Hospital, University of Health Science, Ankara, Turkey., Erdogan I; Department of Hematology, Goztepe Research and Training Hospital, University of Istanbul Medeniyet, Ankara, Turkey., Elıbol T; Department of Hematology, Goztepe Research and Training Hospital, University of Istanbul Medeniyet, Ankara, Turkey., Kızıloz H; Department of Urology, Nevsehir Government Hospital, Nevsehir, Turkey., Aykan MB; Department of Medical Oncology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey., Sayın S; Department of Medical Oncology, School of Medicine, University of Cukurova, Adana, Turkey., Kaptan K; Department of Medical Hematology, Sultan Abdulhamid Han Research and Training Hospital, University of Health Science, Istanbul, Turkey., Soydan E; Department of Hematology, Medicana International Hospital, Ankara, Turkey., Gokmen A; Department of Hematology, Medicana International Hospital, Ankara, Turkey., Esen R; Department of Hematology, Van Yuzuncu Yil School of Medicine, University of Van Yuzuncu Yil, Van, Turkey., Barısta I; Department of Medical Oncology, Hacettepe School of Medicine, University of Hacettepe, Ankara, Turkey., Albayrak M; Department of Hematology, Dıskapı Research and Training Hospital, University of Health Science, Ankara, Turkey., Erturk I; Department of Medical Oncology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey., Yıldız B; Department of Medical Oncology, Medical Park Hospital, Ankara, Turkey., Keskın GY; Department of Medical Oncology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey., Aylı M; Department of Hematology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey., Karadurmus N; Department of Medical Oncology, Gulhane School of Medicine, University of Health Science, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Apr; Vol. 19 (Supplement), pp. S138-S144.
DOI: 10.4103/jcrt.jcrt_355_22
Abstrakt: Introduction and Aim: Primary mediastinal B-cell lymphomas (PMBL) are aggressive B- cell lymphomas. Although the initial treatment models vary in PMBL, appropriate treatment methods are not known. We aim to show real-life data on health outcomes in adult patients with PMBL who received various type of chemoimmunotherapies in Turkey.
Method: We analyzed the data of 61 patients who received treatments for PMBL from 2010 to 2020. The overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) of the patients were evaluated.
Results: 61 patients were observed in this study. The mean age of the study group was 38.4 ± 13.5 years. From among them, 49.2% of the patients were female (n = 30). For first-line therapy, 33 of them had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen (54%). Twenty-five patients had received rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH-R) regimen. The ORR was 77%. The median OS and PFS were as follows: 25 months (95% CI: 20.4-29.4) and 13 months (95% CI: 8.6-17.3), respectively. The OS and PFS at 12 months were 91.3% and 50%, respectively. The OS and PFS at five years were 64.9% and 36.7%, respectively. Median follow-up time period was 20 months (IQR 8.5-38.5).
Conclusion: R-CHOP and DA-EPOCH-R showed good results in PMBL. These remain one of the best determined systemic treatment options for first-line therapy. Also, the treatment was associated with good efficacy and tolerability.
Databáze: MEDLINE
Externí odkaz: